New hope for kids with neuroblastoma: experimental combo enters human testing
NCT ID NCT01711554
First seen Sep 30, 2025 · Last updated Jun 21, 2026 · Updated 32 times
Summary
This early-stage trial tests a combination of three drugs—lenalidomide, dinutuximab, and isotretinoin—in children whose neuroblastoma has not responded to treatment or has come back. The main goal is to find the safest dose of lenalidomide when used with the other drugs. Researchers will also look at how the treatment affects the immune system. The study involves 27 participants and is no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
C S Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
-
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, 30329, United States
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Cook Children's Medical Center
Fort Worth, Texas, 76104, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
UCSF Medical Center-Parnassus
San Francisco, California, 94143, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Chicago Comer Children's Hospital
Chicago, Illinois, 60637, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide, dinutuximab, and isotretinoin
What this could lead to
If this works, it could point toward a new combination treatment for children with neuroblastoma that has not responded to standard therapy or has returned.
What could go wrong
This is a very early phase I trial with only 27 participants, focused on safety and dosing. It is not designed to prove effectiveness, and side effects may be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.